Welcome to our dedicated page for eXoZymes SEC filings (Ticker: EXOZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The eXoZymes Inc. (EXOZ) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. eXoZymes is a Nevada corporation with common stock listed on the Nasdaq Capital Market under the ticker EXOZ, as noted in its Form 8-K reports. Through these filings, the company furnishes information about material events related to its AI-enhanced, cell-free biomanufacturing platform and associated programs.
Recent Form 8-K filings have attached press releases and investor presentations that describe key developments in eXoZymes’ business. These include a press release on the 100-fold scale-up of N-trans-caffeoyltyramine (NCT) production using its exozyme-based platform, with reported conversion levels of over 99% from feedstock to product, and investor materials related to its NCTx business. Other 8-Ks have provided updated investor presentations that outline the company’s focus on exozymes, cell-free biomanufacturing, and highly valuable natural product molecules.
On Stock Titan, investors can review these EXOZ filings alongside AI-powered summaries that explain the context and main points of each document. Real-time updates from the SEC’s EDGAR system help surface new 8-Ks and other forms as they are filed, while AI-generated overviews aim to make complex disclosures easier to understand.
For those tracking eXoZymes, the filings page is a way to see how the company formally reports material events such as technical milestones, investor communications, and business updates tied to its biomanufacturing platform. Users can also look for additional forms, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 when they are available, with AI tools helping to highlight important information within these documents.
eXoZymes Inc.
EXOZYMES INC. Chief Scientific Officer Korman Tyler Paz reported small open-market sales of company common stock. On April 8, Paz sold 750 shares at an average price of $10.0406 per share, followed by another 750 shares on April 9 at $10.525 per share.
Across the two days Paz sold a total of 1,500 shares and now directly holds 729,123 shares of EXOZYMES INC. common stock. The transactions are classified as open-market sales of non-derivative common stock.
eXoZymes Inc. filed a preliminary prospectus supplement to sell shares of its common stock under a shelf registration (Registration No. 333-292781). The offering size and per-share price are redacted in this excerpt. The lead underwriter, MDB Capital, is affiliated with a 47.79% holder, creating a FINRA Rule 5121 conflict; a qualified independent underwriter will participate.
The company states it will use net proceeds to advance its NCT program, related nutraceutical commercialization and R&D, and for general corporate purposes. The filing discloses pilot-scale NCT production at >99% purity and commercial scale-up plans, but many financial and offering specifics are redacted in the provided excerpt.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received equity-based compensation on April 1, 2026. He was granted stock options for 146,437 shares of common stock at an exercise price of $9.49 per share and a restricted stock award of 62,759 shares.
The restricted shares vest quarterly at 3,923 shares, with 15,689 shares vesting immediately and a final 3,917-share installment scheduled on April 1, 2029. The options vest monthly at 3,050 shares, with 36,609 shares vesting immediately and a final 3,078-share installment also on April 1, 2029.
After these awards, Perriman directly holds 62,759 common shares from the restricted stock grant and 146,437 stock options, all granted as compensation rather than through open-market buying or selling.
EXOZYMES INC. reported that Chief Commercial Officer Perriman Damien Alan filed an initial Form 3 as an officer of the company. This filing establishes his status as an insider subject to ongoing ownership and transaction reporting requirements, but it does not list any current holdings or transactions.
Perriman Damien Alan reported acquisition or exercise transactions in this Form 4 filing.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received a grant of 8,887 shares of common stock on 2026-04-01. The shares were awarded as a compensation-related grant at a reported price of $8.44 per share, rather than through an open-market purchase or sale.
Opgenorth Paul Hideo reported acquisition or exercise transactions in this Form 4 filing.
EXOZYMES INC. reported that Vice President of Development Paul Hideo Opgenorth received a grant of 3,999 shares of common stock on April 1, 2026 at a price of $8.44 per share. Following this compensation-related award, his direct holdings increased to 645,149 shares of EXOZYMES common stock.
Exozymes Inc. Vice President-Finance Nawaz Fouad received a stock award of 5,999 shares of common stock. The shares were granted at a value of $8.44 per share and are reported as a grant, award, or other acquisition rather than an open-market purchase. Following this award, his directly held common stock position increased to 9,488 shares.
Korman Tyler Paz reported acquisition or exercise transactions in this Form 4 filing.
Exozymes Inc. reported that Chief Scientific Officer Tyler Paz Korman received a stock grant of 5,332 shares of common stock on April 1, 2026, at a value of $8.44 per share. Following this compensation-related award, Korman directly holds a total of 730,623 common shares.
eXoZymes Inc. filed a current report to make public an updated Investor Presentation for its NCTx business as of March 30, 2026. The company characterizes this under an Other Events item, using the 8-K to furnish the new presentation as Exhibit 99.1.